This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NPS Pharmaceuticals’ President And CEO Dr. Francois Nader Receives Ernst & Young National Entrepreneur Of The Year® 2013 Award In The Life Sciences Category

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief executive officer Francois Nader, M.D. has received the Ernst & Young National Entrepreneur Of The Year ® 2013 Award in the Life Sciences category. This award is regarded as the world’s most prestigious business award for entrepreneurs. Dr. Nader was honored at an awards gala, the culminating event of the EY Strategic Growth Forum ®, on November 16 in Palm Springs, California.

“It’s an honor and a privilege to receive the Ernst & Young National Entrepreneur Of The Year award,” said Dr. Nader. “This wouldn’t be possible without the unwavering dedication and support of the entire NPS team. I look forward to keeping the entrepreneurial spirit alive at NPS as we continue to work to bring innovative therapeutics to patients suffering from rare diseases around the world.”

Dr. Nader joined NPS in 2006 and was appointed president and chief executive officer in March 2008. He led the company’s transformation into a global commercial-stage biopharmaceutical company focused on bringing innovative treatments to patients with rare diseases. During his tenure, Dr. Nader created a values-driven culture-by-design that contributed to NPS being named as one of the top 100 companies to work for in New Jersey for two consecutive years.

Earlier this year, NPS launched Gattex® (teduglutide [rDNA Origin]) for injection, its first medication approved by the U.S. Food and Drug Administration (FDA) and the European Commission. In March, Dr. Nader established NPS as a global commercial rare disease company by reacquiring the worldwide rights to its two lead drugs from Takeda GmbH. In October, the company submitted its Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its second orphan product Natpara® (recombinant human parathyroid hormone 1-84, rhPTH(1-84)) for the treatment of hypoparathyroidism.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 +0.97 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs